Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 2 Breast Neoplasms 2 Neutropenia 1 Lymphoma, T-Cell 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphoma 1 Lymphangioleiomyomatosis 1 Hematologic Neoplasms 1 Burkitt Lymphoma 1

Interventions

Sirolimus 9 Everolimus 5 Imatinib Mesylate 2 temsirolimus 1 saracatinib 1 nintedanib 1 carbon-11 acetate 1 Valproic Acid 1 Sugars 1 Simvastatin 1 Resveratrol 1 Octreotide 1 Loratadine 1 Letrozole 1 Immunoglobulin G 1 Hydroxychloroquine 1 Glutamine 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Celecoxib 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lymphangioleiomyomatosis × Loratadine × Clear all

NCT05190627 2022-01-27

LORALAM

Institut d'Investigació Biomèdica de Bellvitge

Phase 2 Unknown

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡